AI-Driven Hip Exoskeleton Control for Diverse Users and Walking Tasks
AI-Driven Hip Exoskeleton Control Framework That Rapidly Generalizes to a Broad Range of Users and Real-World Locomotor Tasks
The goal of this clinical trial is to evaluate the feasibility of a prototype artificial intelligence (AI)-based controller for a lightweight hip exoskeleton across a broad range of users, including healthy younger adults (18-39 years) and older adults (65 years and older). The main questions it aims to answer are:
- Can the AI-based controller accurately estimate gait phase in real time across younger and older adults?
- How does hip exoskeleton assistance change walking energy cost, mechanics, and muscle activity?
Researchers will compare walking with powered hip exoskeleton assistance to walking without the exoskeleton and walking while wearing the exoskeleton with no assistance (zero torque).
Participants will:
- Complete a short screening and frailty assessment
- Walk on a treadmill under different conditions with and without the hip exoskeleton during 2 to 5 lab visits
- Wear motion capture markers, muscle activity (EMG) sensors, and a mask that measures breathing to estimate energy use
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
This study is funded by the National Institute of Biomedical Imaging and Bioengineering (R21EB037268) and conducted at the University of Texas at Austin in collaboration with Carnegie Mellon University. The CMU Hip Exoskeleton is a research prototype with powered hip joints for flexion and extension (peak torque 18 Nm, total weight 3.5 kg). Its controller uses joint angle and user-state estimates to command assistive torque, limited to less than 0.2 Nm/kg (at most about 30% of typical biological hip moments during walking), so it supplements rather than overrides the user's own muscle effort.
During each visit, participants walk on a force-instrumented treadmill at 1.25 m/s with safety harness and handrails. Researchers record whole-body motion capture, ground reaction forces, inertial measurement unit data, lower-limb electromyography, and metabolic energy expenditure via open-circuit indirect calorimetry. Walking conditions include no exoskeleton, exoskeleton worn with zero torque, and powered exoskeleton assistance. Outcomes will be compared across conditions and between younger and older adults using repeated-measures statistical analysis.
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Owen Beck, PhD
- Número de telefone: 512-232-6025
- E-mail: owenbeck@austin.utexas.edu
Locais de estudo
-
-
Texas
-
Austin, Texas, Estados Unidos, 78712
- Recrutamento
- University of Texas at Austin
-
Contato:
- Owen Beck, PhD
- Número de telefone: 512-232-6025
- E-mail: owenbeck@austin.utexas.edu
-
Contato:
- Dylan Page
- Número de telefone: 319-440-0869
- E-mail: dmp3799@my.utexas.edu
-
Investigador principal:
- Owen Beck, PhD
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Age 18 to 39 years (younger adult group) or 65 years and older (older adult group)
- Willing and able to provide informed consent
- Able to walk independently without assistance
- No known cardiovascular, metabolic, or renal disease, and no signs or symptoms suggestive of such disease
- Cleared for light- to moderate-intensity exercise without the need for medical clearance under American College of Sports Medicine (ACSM) preparticipation screening guidelines
Exclusion Criteria:
- Age 40 to 64 years
- Leg surgery within the past 5 years
- Orthopedic disability that could impair movement or limit participation in the exercise protocol
- Neurologic disorder that may affect neuromuscular function or gait (e.g., stroke, Parkinson's disease, peripheral neuropathy, traumatic brain injury)
- Known metabolic or cardiovascular disease (hypertension alone is not exclusionary), or requiring medical clearance under ACSM guidelines without having obtained it
- Metal implants in the lower extremities, cardiac pacemaker, or other implanted electronic device
- Pregnancy
- History of seizure disorder or fainting (syncope)
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Viabilidade do dispositivo
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: Hip Exoskeleton Walking
Healthy younger adults (18-39 years) and older adults (65+ years) walk on an instrumented treadmill under multiple conditions across 2-5 lab visits: no exoskeleton, wearing the CMU Hip Exoskeleton with zero torque, and with powered assistance from the AI-driven hip exoskeleton controller (assistance limited to <0.2 Nm/kg). The primary objective is to evaluate real-time gait phase estimation accuracy of the prototype controller across users; metabolic cost, biomechanics, and muscle activity are recorded as secondary measures. |
A lightweight (3.5 kg) research hip exoskeleton developed at Carnegie Mellon University with powered hip flexion/extension joints, a backpack-mounted computer and battery, and thigh and waist interfaces secured with straps. An AI-driven controller estimates the user's gait state from joint angle and wearable sensor data and commands assistive hip torque in real time, limited to <0.2 Nm/kg (peak device torque 18 Nm). Participants walk on a treadmill with powered assistance, with the device worn at zero torque, and without the device. The device was determined by the UT Austin IRB to be a non-significant risk device.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Gait Phase Estimation Error of the AI-Driven Hip Exoskeleton Controller
Prazo: Day 1
|
Root-mean-square error (RMSE) between the controller's real-time gait phase estimate and ground-truth gait phase derived from force-instrumented treadmill data during powered hip exoskeleton walking, reported as percent of the gait cycle (%). Used to evaluate feasibility of the prototype controller across younger and older adult users. |
Day 1
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Net Metabolic Power During Powered Hip Exoskeleton Walking
Prazo: Day 1
|
Net metabolic power (W/kg), measured by open-circuit indirect calorimetry with resting value subtracted, during treadmill walking at 1.25 m/s with powered hip exoskeleton assistance. |
Day 1
|
|
Peak Hip Joint Moment During Powered Hip Exoskeleton Walking
Prazo: Day 1
|
Peak biological hip extension moment (Nm/kg), computed from motion capture and force-instrumented treadmill data, during treadmill walking with powered hip exoskeleton assistance. |
Day 1
|
|
Lower-Limb Muscle Activity During Powered Hip Exoskeleton Walking
Prazo: Day 1
|
Average electromyography (EMG) amplitude normalized to maximum voluntary contraction (%MVC), averaged across eight recorded lower-limb muscles, during treadmill walking with powered hip exoskeleton assistance. |
Day 1
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Investigador principal: Inseung Kang, PhD, Carnegie Mellon University
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Outros números de identificação do estudo
Outros números de identificação do estudo
- STUDY2026_00000477
- R21EB037268 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
De-identified individual participant data underlying published results will be shared, including biomechanics (motion capture, ground reaction forces), electromyography, metabolic, and exoskeleton sensor/controller data, along with participant characteristics (age group, sex, height, mass). Identifiable information, including video recordings, will not be shared.
Prazo de Compartilhamento de IPD
Data will be made available no later than the time of associated publication or the end of the award period, whichever comes first, and will remain available for at least 5 years.
Critérios de acesso de compartilhamento IPD
De-identified data and supporting information will be deposited in a public data repository and made openly available to researchers without restriction, subject to the repository's terms of use.
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- ANALYTIC_CODE
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .